96
Participants
Start Date
January 1, 2021
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2024
Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy
Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.
RECRUITING
Tianjin Medical University Cancer Institute&Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital
OTHER